AT-101 + docetaxel + prednisone

**AT-101 + docetaxel + prednisone** is an experimental combination therapy used in oncology clinical trials, primarily investigated in metastatic castration-resistant prostate cancer and other advanced solid malignancies. AT-101 (R-(-)-gossypol acetic acid) is a small molecule, oral BH3 mimetic that inhibits anti-apoptotic Bcl-2 family proteins, promoting caspase activation and apoptosis in tumor cells. Docetaxel is a microtubule inhibitor that disrupts cell division, while prednisone is a corticosteroid with anti-inflammatory and immunosuppressive effects and is often used in prostate cancer regimens to mitigate symptoms and side effects. This combination aims to induce synergistic tumor cell killing through complementary mechanisms: mitochondrial apoptosis (AT-101), mitotic arrest (docetaxel), and hormonal/anti-inflammatory modulation (prednisone). Clinical trials have tested this triplet particularly in patients with advanced, treatment-refractory prostate cancer and observed some benefit, especially in high-risk subsets or patients with prolonged disease control, though overall efficacy was limited and tolerability was generally modest[1][4].

Other names

AT-101 + docetaxel + prednisone